Antibody–drug conjugatesand small molecule–drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents …

Abstract Click to copy section link Section link copied! Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which typically do not preferentially localize at the tumor site and cause toxicity to normal organs, preventing dose escalation to therapeutically active regimens. In principle, antibodies and other ligands could be used for the selective pharmacodelivery of cytotoxic agents to the neoplastic mass. For many years, the availability of ligands, capable of selective internalization into tumor cells, has been considered to be an essential requirement for the development of targeted cytotoxics.

This assumption, however, has recently been challenged on the basis of therapeutic data obtained with noninternalizing drug conjugates. Moreover, quantitative evaluations of the tumor targeting properties of antibodies and of small organic ligands have provided new insights for the implementation of optimal strategies for the development of targeted cytotoxics. In this article, we highlight opportunities and challenges associated with the clinical and industrial development of antibody–drug conjugates and small molecule–drug conjugates for cancer therapy. ACS Publications Copyright © 2015 American Chemical Society Subjects what are subjects Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article.

Biopolymers Cancer Cancer therapy Immunology Peptides and proteins